With a focus on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, pulmonary fibrosis, nontuberculous mycobacterial (NTM) lung disease, and fluid overload associated with heart failure and chronic kidney disease. This regional role is responsible for leading scientific engagement with key opinion leaders (KOLs) academic medical centers and healthcare professionals, driving advanced medical education initiatives, and providing strategic insights to shape clinical development and medical strategy.